NEO250117C24000
- 0.00
- 0.000.00%
NeoGenomics Newsroom
Raymond James Maintains NeoGenomics(NEO.US) With Hold Rating
NeoGenomics Shares Fall on CEO's Plan to Retire
Needham Maintains NeoGenomics(NEO.US) With Buy Rating, Maintains Target Price $19
Express News | Needham Reiterates Buy on NeoGenomics, Maintains $19 Price Target
NeoGenomics Shares Are Falling Today: What's Going On?
NeoGenomics Analyst Ratings
NeoGenomics: Strong Buy Amid Leadership Transition and Sustained Growth
NeoGenomics Down Over 15%, On Track for Largest Percent Decrease Since December 2023 -- Data Talk
Express News | NeoGenomics Shares Are Trading Lower. The Company Announced Its CEO Will Retire Effective the First of April
Craig-Hallum Maintains NeoGenomics(NEO.US) With Buy Rating
Craig-Hallum Releases a Buy Rating on NeoGenomics (NEO)
NeoGenomics CEO Chris Smith to Retire; Tony Zook to Take Helm
NeoGenomics Announces CEO Transition and Leadership Change
NeoGenomics Backs FY24 Revenue View $655M-$667M, Consensus $662M
NeoGenomics Backs FY Rev $655M-$667M >NEO
NeoGenomics: Tony Zook Will Assume the Role of CEO >NEO
Express News | Neogenomics Inc - Reaffirms Full-Year 2024 Guidance
Express News | Neogenomics Inc - Chris Smith to Retire as CEO of Neogenomics Effective April 1, 2025
NeoGenomics Announces Chief Executive Officer Succession
Express News | Neogenomics Announces Chief Executive Officer Succession